BackAllergy Therapeutics plc Overview

Allergy Therapeutics plc Receivables

Track Allergy Therapeutics plc's receivables ($13M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$12.89M
↑ 17.79% YoYΔ $1.95M vs prior year quarter

Peer trimmed avg / median

Loading

Allergy Therapeutics plc Receivables History

Loading

Allergy Therapeutics plc vs. peers: Receivables Comparison

Loading

Allergy Therapeutics plc Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Allergy Therapeutics plc (AGYTF) FAQ

The latest receivables for AGYTF is $13M as of June 2026. That compares with $11M in the prior-year period — up 17.8% year over year. Investors often review this figure alongside Allergy Therapeutics plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGYTF's receivables moved from $11M to $13M — a 17.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allergy Therapeutics plc's operating scale or balance-sheet position.

A receivables figure of $13M for AGYTF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGYTF's receivables ($13M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers